US4943A - Harness-buckle - Google Patents

Harness-buckle Download PDF

Info

Publication number
US4943A
US4943A US4943DA US4943A US 4943 A US4943 A US 4943A US 4943D A US4943D A US 4943DA US 4943 A US4943 A US 4943A
Authority
US
United States
Prior art keywords
tug
box
plate
buckle
harness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Publication date
Application granted granted Critical
Publication of US4943A publication Critical patent/US4943A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A44HABERDASHERY; JEWELLERY
    • A44BBUTTONS, PINS, BUCKLES, SLIDE FASTENERS, OR THE LIKE
    • A44B11/00Buckles; Similar fasteners for interconnecting straps or the like, e.g. for safety belts
    • A44B11/02Buckles; Similar fasteners for interconnecting straps or the like, e.g. for safety belts frictionally engaging surface of straps
    • A44B11/06Buckles; Similar fasteners for interconnecting straps or the like, e.g. for safety belts frictionally engaging surface of straps with clamping devices
    • A44B11/10Buckles; Similar fasteners for interconnecting straps or the like, e.g. for safety belts frictionally engaging surface of straps with clamping devices sliding wedge
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T24/00Buckles, buttons, clasps, etc.
    • Y10T24/40Buckles
    • Y10T24/4002Harness
    • Y10T24/4012Clamping
    • Y10T24/4019Sliding part or wedge

Definitions

  • I construct a metallic plate with a rough front surface as represented in Fig. 4, and on the back side of this plate I affix the roller e Fig. 5, which runs in grooves near each outer edge of the plate, and is held in its proper place by the cap f, Fig. 5.
  • a band g, Figs. 4 and 5 is attached to the front end of this plate through which the tug or draw strap is passed.
  • the draw tug i Fig. 1 is passed in at the. small end of lthe box a, leaving the plateresting upon the back side of the box, as shown at k. Fig. l.I
  • the plate and roller will be drawn into the taperlng box a, and thus press the tug i i'irmly between the front side of the box and the sliding plate, and an increase of draft upon the tug will increase the pressure upon the tug within the box, thereby holding it iirmly 1n its proper place.
  • the plate can be moved upon the tug by taking hold of the band g, Figs. 4 and 5, thus the tug can be lengthened or shortened at pleasure or entirely drawn out of the metallic box.
  • the pin c, Figs. 2 and 3 may be dispensed with and the hame tug riveted to an extended portion of the back plate of the metallic box.
  • the box may be made of plated metal, plate brass, or sheet iron, or 1t may be cast.
  • the plate and roller may be made of either cast or wrought metal, the whole should correspond in size and strength to the purpose for which it is intended.
  • the style of finish should also correspond with Vthe other portions of the harness.
  • attachments indicated by rthe dotted lines at n, Fig. 3 may be afixed to each side of the box.
  • the breech strap may pass into the box with the tug, or which is better, pass through an aperture 0 Fig. 3, in the back plate of the box. This aperture may, if desired, be made in the front plate of the box.

Description

UNITED` STATES PATENT 'OFFICE WILLIAM D. HILLIS, OF CUYAHOGA FALLS, OHIO.
HARNESS-BUCKLE.
Specification of Letters Patent No. 4,943, dated January 26, 1847.
To all whom t may concern.'
Be it known that I, WILLIAM D. I-IILLrs, of Cuyahoga Falls, in the county of Summit and State of Ohio, have invented a new and Improved Mode of Fastening Tugs or Draw-Straps of Harness to Hame-Tugs; and I do hereby declare that the following is a full and exact description of the construction and operation of the same, reference being had to the annexed drawings, making a part of this specification, in which- Figure l is a perspective view of the model, embracing the hame tug, buckle, and a part of the tug or draw strap. Fig. 2, a perspective view of the buckle detached from the hame tug and draw strap. Figs. 3, 4 and 5 are sectional views of the same in different positions. Figs. 2, 3, 4 and 5 being drawn on a larger scale than Fig. l.
The nature of my invention consists in the construction of an apparatus' which will serve all the purposes of the common buckle, r
without the use of the tongue, and the consequent necessity of perforating the draw strap with holes, and also the convenience of taking up, or adjusting the draw tug to lany desired length.
To enable othersI skilled in the art, to make and use my invention, I will proceed to describe its const-ruct-ion and operation.
I construct a metallic oblong box, let a, Figs. l, 2 and 3, open at bothV ends, of equal width perpendicularly, but of unequal thickness, thefront and back sides of the box forming relatively to each other an inclined plane, the opening in the front end of this box is suiiiciently large to admit the metallic plate and roller hereafterto be described, together with the draw tug or strap.
The parallel sides of the box which are marked b, b, Fig. 3 extend farther than the back plate, and receives the pin c Figs. 2 and 3, around which the hame tug passes as represented at cl, Fig. 1. A
I construct a metallic plate with a rough front surface as represented in Fig. 4, and on the back side of this plate I affix the roller e Fig. 5, which runs in grooves near each outer edge of the plate, and is held in its proper place by the cap f, Fig. 5.
A band g, Figs. 4 and 5 is attached to the front end of this plate through which the tug or draw strap is passed. I Vplace this plate with the roller, inside of the box a,
ythe roller resting upon the back side Vof the A box and ,thel rough side ofl the plate being 1n front as represented at 7L, Fig. 2. The draw tug i Fig. 1 is passed in at the. small end of lthe box a, leaving the plateresting upon the back side of the box, as shown at k. Fig. l.I Now, by pulling upon the tug, the plate and roller will be drawn into the taperlng box a, and thus press the tug i i'irmly between the front side of the box and the sliding plate, and an increase of draft upon the tug will increase the pressure upon the tug within the box, thereby holding it iirmly 1n its proper place. In klengthening or shortening the tug, the plate can be moved upon the tug by taking hold of the band g, Figs. 4 and 5, thus the tug can be lengthened or shortened at pleasure or entirely drawn out of the metallic box.
The sheath m, Fig. l, into which the end of the tug passes after leaving the metal box, is attached as'usual to the hame tug and should extend to the end which is attached to theV metal box.
In theconstruction of this buckle orfastening, the pin c, Figs. 2 and 3 may be dispensed with and the hame tug riveted to an extended portion of the back plate of the metallic box. The box may be made of plated metal, plate brass, or sheet iron, or 1t may be cast. The plate and roller may be made of either cast or wrought metal, the whole should correspond in size and strength to the purpose for which it is intended. The style of finish should also correspond with Vthe other portions of the harness.
If it is desired to fasten the pad and girth y to the tug, attachments indicated by rthe dotted lines at n, Fig. 3, may be afixed to each side of the box. The breech strap may pass into the box with the tug, or which is better, pass through an aperture 0 Fig. 3, in the back plate of the box. This aperture may, if desired, be made in the front plate of the box.
The advantages of this method of fastening over the common tongue buckle, are various, and consist first, in beauty. It will be a great ornament to a harness. Second, in strength, about one half of the strength of t-he common tug is lost by the holes for the buckle tongue. Third, in economy of leather. A tug with this fastening requires about one half the usual quantity of leather for the same strength. Fourth, durability, the tongue of the comon buckle tears, and the ring indents and will soon materially injure the tug. But With this fastening, the large surface pressing the tug, cannot indent it. Fifth, in convenience. The tug may be lengthened or shortened in a moment of time, and with no trouble. Finally, its
advantages over other known methods of fastening the tug, consists in the convenience with which it is Worked, in lengthening or shortening the tug; the little Wear to the tug from the large surface pressing it, and in its being undivided7 and in security, as when the tug is loosened, upon being drawn,
WILLIAM D. HILLIS.
Vitnesses G. C. I-IUBBARD, H. PAUL.
US4943D Harness-buckle Expired - Lifetime US4943A (en)

Publications (1)

Publication Number Publication Date
US4943A true US4943A (en) 1847-01-26

Family

ID=2065244

Family Applications (1)

Application Number Title Priority Date Filing Date
US4943D Expired - Lifetime US4943A (en) Harness-buckle

Country Status (1)

Country Link
US (1) US4943A (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070222256A1 (en) * 2006-03-23 2007-09-27 Jeffrey Valentage Hybrid door core and trim module with integrated components
US20090006359A1 (en) * 2007-06-28 2009-01-01 Oracle International Corporation Automatically finding acronyms and synonyms in a corpus
WO2013174432A1 (en) 2012-05-24 2013-11-28 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
EP2687202A1 (en) 2009-07-31 2014-01-22 F. Hoffmann-La Roche AG Subcutaneous anti-her2 antibody formulation
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2020163589A1 (en) 2019-02-08 2020-08-13 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
WO2021062085A1 (en) 2019-09-27 2021-04-01 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
WO2021097110A1 (en) 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
WO2021127404A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021250284A1 (en) 2020-06-12 2021-12-16 Eligo Bioscience Specific decolonization of antibiotic resistant bacteria for prophylactic purposes
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2022020716A1 (en) 2020-07-24 2022-01-27 Genentech, Inc. Heterocyclic inhibitors of tead for treating cancer
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2022076462A1 (en) 2020-10-05 2022-04-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022171745A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
EP4067347A1 (en) 2016-05-24 2022-10-05 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
WO2022251296A1 (en) 2021-05-25 2022-12-01 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
EP4119583A1 (en) 2008-01-30 2023-01-18 Genentech, Inc. Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
EP4155415A1 (en) 2016-02-29 2023-03-29 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
EP4249917A2 (en) 2018-09-21 2023-09-27 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
EP4335931A2 (en) 2015-05-29 2024-03-13 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
US20070222256A1 (en) * 2006-03-23 2007-09-27 Jeffrey Valentage Hybrid door core and trim module with integrated components
US20090006359A1 (en) * 2007-06-28 2009-01-01 Oracle International Corporation Automatically finding acronyms and synonyms in a corpus
EP4119583A1 (en) 2008-01-30 2023-01-18 Genentech, Inc. Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
EP2687202A1 (en) 2009-07-31 2014-01-22 F. Hoffmann-La Roche AG Subcutaneous anti-her2 antibody formulation
EP4339212A2 (en) 2009-07-31 2024-03-20 F. Hoffmann-La Roche AG Subcutaneous anti-her2 antibody formulation
WO2013174432A1 (en) 2012-05-24 2013-11-28 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
EP4335931A2 (en) 2015-05-29 2024-03-13 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
EP4155415A1 (en) 2016-02-29 2023-03-29 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP4067347A1 (en) 2016-05-24 2022-10-05 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP4249917A2 (en) 2018-09-21 2023-09-27 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
WO2020163589A1 (en) 2019-02-08 2020-08-13 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
WO2021062085A1 (en) 2019-09-27 2021-04-01 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
WO2021097110A1 (en) 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
WO2021127404A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021250284A1 (en) 2020-06-12 2021-12-16 Eligo Bioscience Specific decolonization of antibiotic resistant bacteria for prophylactic purposes
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2022020716A1 (en) 2020-07-24 2022-01-27 Genentech, Inc. Heterocyclic inhibitors of tead for treating cancer
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2022076462A1 (en) 2020-10-05 2022-04-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022171745A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
WO2022251296A1 (en) 2021-05-25 2022-12-01 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives

Similar Documents

Publication Publication Date Title
US4943A (en) Harness-buckle
US3001A (en) Method of coupling straps as a substitute for a buckle
US5476A (en) Harness-saddle
US377709A (en) Assighoe to him
US600478A (en) Harness-loop
US130604A (en) Improvement in halters
US111502A (en) Improvement in harness saddle-trees
US155796A (en) Improvement in bridle-rosettes and gag-swivels
US392306A (en) Hame-tug
US347533A (en) Breast-ring attachment
US7265A (en) Habjstess-hahe
US385687A (en) Joseph j
US69628A (en) Improved belt-clasp
US113902A (en) Improvement in buckles
US225242A (en) Harness-saddle
US150161A (en) Improvement in horse-collars
US102333A (en) Improvement in trace-buckles
US43931A (en) Improvement in toilet-combs
US350216A (en) James stanley
US403947A (en) Hame-tug
USRE7129E (en) Improvement in buckle-fastenings
US206307A (en) Improvement in shaft-tugs
US743492A (en) Hame-tug.
US385082A (en) Hiram j
US118137A (en) Improvement in harness-saddles